Intellipharmaceutics International Inc.

As of August 31, 2023, Intellipharmaceutics International Inc. has 33.09M shares outstanding.

These figures are as of August 31, 2023. The price-to-sales ratio is 2.93, and the price-to-book ratio stands at -0.05.

These figures are as of August 31, 2023. The EV/Sales ratio of 4.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Intellipharmaceutics International Inc. trades at an EV/FCF ratio of 12.60, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of August 31, 2023, Intellipharmaceutics International Inc. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -17.23, indicating conservative leverage, while an interest coverage ratio of -10.07 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended August 31, 2023. Return on assets (ROA) is negative at -211.39, reflecting losses generated across the asset base.

Over the twelve months ended August 31, 2023, Intellipharmaceutics International Inc. posted a gross margin of 98.07, reflecting its pricing power and cost economics. The operating margin of -279.57 and net profit margin of -350.72 provide insight into operational efficiency.

These figures cover the twelve months ended August 31, 2023. Free cash flow yield stands at 4.55, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -7.55, meaning Intellipharmaceutics International Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Intellipharmaceutics International Inc.'s most recent stock split took place on September 14, 2018 with a 10:1 split ratio.

As of August 31, 2023, Intellipharmaceutics International Inc. has an Altman Z-Score of -111.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.